Summary

Esoteric Testing Market Summary

The global esoteric testing market size was estimated at USD 24.6 billion in 2024 and is projected to reach USD 47.98 billion by 2030, growing at a CAGR of 11.8% from 2025 to 2030. The market growth can be attributed to the increasing demand for early disease diagnosis and the rising prevalence of cancer, which impels the demand for safer diagnostic options.

According to the National Center for Biotechnology Information (NCBI), around 2,041,910 cancer cases will be diagnosed, with 618,120 cancer deaths expected in the U.S. in 2025. The lucrative growth potential of currently available esoteric testing options and high demand for technologically advanced and affordable tests are the factors expected to drive the market growth in the coming years. Moreover, the adoption of advanced esoteric testing technologies in independent and reference laboratories is anticipated to drive the esoteric testing industry.

Esoteric tests are crucial in identifying particular genetic markers and biomarkers to develop personalized treatment plans. For instance, in February 2023, F. Hoffmann-La Roche Ltd announced the extension of its collaboration with Janssen to advance personalized healthcare by focusing on companion diagnostics, further strengthening research and innovation activities. Thus, the rising preference for personalized medicine worldwide is anticipated to boost product demand in the coming years. The growing inclination of surgeons and patients for esoteric tests due to technological advancements, such as real-time Polymerase Chain Reaction (PCR), next-generation sequencing, and others, is anticipated to be a key driver of the rising demand for advanced diagnostics. Examples of esoteric diagnostics are genetic tests for uncommon illnesses, specialized tests for unusual infections, and advanced biomarker assays. In contrast to standard blood or urine testing, esoteric diagnostics are usually outsourced to reference labs equipped with the necessary equipment and personnel. These tests can be beneficial in specific therapeutic settings or scientific investigations owing to their high specificity and effectiveness, even though the demand is usually low due to the high cost.

The growing trend toward personalized treatment has led to a significant increase in the need for esoteric tests. To identify targeted therapies specific to each patient, these specialized tests examine a patient's genetic composition, protein profiles, and biomarkers. With the growing adoption of personalized medicine and precision diagnostics due to increased awareness, targeted and customized testing strategies are becoming increasingly necessary. An increase in initiatives undertaken by the government to provide various facilities, such as reimbursement for diagnostic tests, is another major factor anticipated to drive the market. Many healthcare institutions are working with laboratories to integrate different esoteric tests.

Over the last few years, the coverage for these procedures by policies offered by government and private insurance providers has increased. Hence, supportive reimbursement and regulatory policies also act as key drivers of the market. Medicare and Medicaid have increased reimbursement for various esoteric tests. In addition, private insurers are collaborating with esoteric labs to offer patients affordable tests, which lower out-of-pocket costs for patients and increase access to esoteric tests, thereby driving market growth.

Esoteric Testing Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels as well as provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the esoteric testing market report on the basis of product, technology, and region:

• Type Outlook (Revenue, USD Million, 2018 - 2030)
• Oncology testing
• Infectious disease testing
• Genetic testing
• Endocrinology testing
• Toxicology testing
• Neurology testing
• Others
• Technology Outlook (Revenue, USD Million, 2018 - 2030)
• Chemiluminescence immunoassay
• Enzyme-linked immunosorbent assay
• Mass spectrometry
• Real time polymerase chain reaction
• Flow cytometry
• Others
• End Use Outlook (Revenue, USD Million, 2018 - 2030)
• Hospital-based laboratories
• Independent and reference laboratories
• Other
• Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
o U.S.
o Canada
o Mexico
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Denmark
o Sweden
o Norway
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o Thailand
o Rest of Asia Pacific
• Latin America
o Brazil
o Argentina
o Rest of Latin America
• Middle East & Africa (MEA)
o South Africa
o Saudi Arabia
o UAE
o Kuwait

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Technology
1.2.3. End Use
1.2.4. Regional Scope
1.2.5. Estimates and Forecasts Timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.4.5. Details of Primary Research
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type Outlook
2.2.2. Technology Outlook
2.2.3. End Use Outlook
2.2.4. Regional Outlook
2.3. Competitive Insights
Chapter 3. Esoteric Testing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Esoteric Testing Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrant
3.3.1.5. Competitive Rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political Landscape
3.3.2.2. Technological Landscape
3.3.2.3. Economic Landscape
Chapter 4. Esoteric Testing Market: Type Estimates & Trend Analysis
4.1. Type Segment Dashboard
4.2. Esoteric Testing Market: Type Movement Analysis
4.3. Global Esoteric Testing Market Size & Trend Analysis, By Type, 2018 to 2030 (USD Million)
4.4. Oncology Testing
4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.5. Infectious Disease Testing
4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.6. Genetic Testing
4.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.7. Endocrinology Testing
4.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.8. Toxicology Testing
4.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.9. Neurology Testing
4.9.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.10. Others
4.10.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 5. Esoteric Testing Market: Technology Estimates & Trend Analysis
5.1. Technology Segment Dashboard
5.2. Esoteric Testing Market: Technology Movement Analysis
5.3. Global Esoteric Testing Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
5.4. Chemiluminescence Immunoassay
5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.5. Enzyme-linked Immunosorbent Assay
5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.6. Mass Spectrometry
5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.7. Real Time Polymerase Chain Reaction
5.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.8. Flow Cytometry
5.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.9. Others
5.9.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 6. Esoteric Testing Market: End Use Estimates & Trend Analysis
6.1. Type Segment Dashboard
6.2. Esoteric Testing Market: End Use Movement Analysis
6.3. Global Esoteric Testing Market Size & Trend Analysis, By End Use, 2018 to 2030 (USD Million)
6.4. Hospital-based Laboratories
6.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5. Independent and Reference Laboratories
6.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.6. Other
6.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 7. Esoteric Testing Market: Regional Estimates & Trend Analysis
7.1. Regional Market Dashboard
7.2. Regional Market Share Analysis, 2024 & 2030
7.3. Continuous Bioprocessing Market By Region: Key Takeaways
7.4. North America
7.4.1. U.S.
7.4.1.1. Key Country Dynamics
7.4.1.2. Regulatory Framework/ Reimbursement Structure
7.4.1.3. Competitive Scenario
7.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.4.2. Canada
7.4.2.1. Key Country Dynamics
7.4.2.2. Regulatory Framework/ Reimbursement Structure
7.4.2.3. Competitive Scenario
7.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.4.3. Mexico
7.4.3.1. Key Country Dynamics
7.4.3.2. Regulatory Framework/ Reimbursement Structure
7.4.3.3. Competitive Scenario
7.4.3.4. Mexico Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.5. Europe
7.5.1. UK
7.5.1.1. Key Country Dynamics
7.5.1.2. Regulatory Framework/ Reimbursement Structure
7.5.1.3. Competitive Scenario
7.5.1.4. UK Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.5.2. Germany
7.5.2.1. Key Country Dynamics
7.5.2.2. Regulatory Framework/ Reimbursement Structure
7.5.2.3. Competitive Scenario
7.5.2.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.5.3. France
7.5.3.1. Key Country Dynamics
7.5.3.2. Regulatory Framework/ Reimbursement Structure
7.5.3.3. Competitive Scenario
7.5.3.4. France Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.5.4. Italy
7.5.4.1. Key Country Dynamics
7.5.4.2. Regulatory Framework/ Reimbursement Structure
7.5.4.3. Competitive Scenario
7.5.4.4. Italy Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.5.5. Spain
7.5.5.1. Key Country Dynamics
7.5.5.2. Regulatory Framework/ Reimbursement Structure
7.5.5.3. Competitive Scenario
7.5.5.4. Spain Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.5.6. Denmark
7.5.6.1. Key Country Dynamics
7.5.6.2. Regulatory Framework/ Reimbursement Structure
7.5.6.3. Competitive Scenario
7.5.6.4. Denmark Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.5.7. Sweden
7.5.7.1. Key Country Dynamics
7.5.7.2. Regulatory Framework/ Reimbursement Structure
7.5.7.3. Competitive Scenario
7.5.7.4. Sweden Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.5.8. Norway
7.5.8.1. Key Country Dynamics
7.5.8.2. Regulatory Framework/ Reimbursement Structure
7.5.8.3. Competitive Scenario
7.5.8.4. Norway Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.6. Asia Pacific
7.6.1. Japan
7.6.1.1. Key Country Dynamics
7.6.1.2. Regulatory Framework/ Reimbursement Structure
7.6.1.3. Competitive Scenario
7.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.6.2. China
7.6.2.1. Key Country Dynamics
7.6.2.2. Regulatory Framework/ Reimbursement Structure
7.6.2.3. Competitive Scenario
7.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.6.3. India
7.6.3.1. Key Country Dynamics
7.6.3.2. Regulatory Framework/ Reimbursement Structure
7.6.3.3. Competitive Scenario
7.6.3.4. India Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.6.4. South Korea
7.6.4.1. Key Country Dynamics
7.6.4.2. Regulatory Framework/ Reimbursement Structure
7.6.4.3. Competitive Scenario
7.6.4.4. South Korea Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.6.5. Australia
7.6.5.1. Key Country Dynamics
7.6.5.2. Regulatory Framework/ Reimbursement Structure
7.6.5.3. Competitive Scenario
7.6.5.4. Australia Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.6.6. Thailand
7.6.6.1. Key Country Dynamics
7.6.6.2. Regulatory Framework/ Reimbursement Structure
7.6.6.3. Competitive Scenario
7.6.6.4. Thailand Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.7. Latin America
7.7.1.1. Key Country Dynamics
7.7.1.2. Regulatory Framework/ Reimbursement Structure
7.7.1.3. Competitive Scenario
7.7.1.4. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Regulatory Framework/ Reimbursement Structure
7.7.2.3. Competitive Scenario
7.7.2.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Regulatory Framework/ Reimbursement Structure
7.7.3.3. Competitive Scenario
7.7.3.4. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.8. Middle East & Africa (MEA)
7.8.1.1. Key Country Dynamics
7.8.1.2. Regulatory Framework/ Reimbursement Structure
7.8.1.3. Competitive Scenario
7.8.1.4. Middle East & Africa (MEA)Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.8.2. Argentina
7.8.2.1. Key Country Dynamics
7.8.2.2. Regulatory Framework/ Reimbursement Structure
7.8.2.3. Competitive Scenario
7.8.2.4. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.8.3. South Africa
7.8.3.1. Key Country Dynamics
7.8.3.2. Regulatory Framework/ Reimbursement Structure
7.8.3.3. Competitive Scenario
7.8.3.4. South Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.8.4. South Arabia
7.8.4.1. Key Country Dynamics
7.8.4.2. Regulatory Framework/ Reimbursement Structure
7.8.4.3. Competitive Scenario
7.8.4.4. South Arabia Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.8.5. UAE
7.8.5.1. Key Country Dynamics
7.8.5.2. Regulatory Framework/ Reimbursement Structure
7.8.5.3. Competitive Scenario
7.8.5.4. UAE Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.8.6. Kuwait
7.8.6.1. Key Country Dynamics
7.8.6.2. Regulatory Framework/Reimbursement Structure
7.8.6.3. Competitive Scenario
7.8.6.4. Kuwait Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. Key Company Heat Map Analysis, 2024
8.4. Company Profiles
8.4.1. Labcorp.
8.4.1.1. Company Overview
8.4.1.2. Financial Performance
8.4.1.3. Type Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. OPKO HEALTH, INC.
8.4.2.1. Company Overview
8.4.2.2. Financial Performance
8.4.2.3. Type Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. Quest Diagnostics Incorporated
8.4.3.1. Company Overview
8.4.3.2. Financial Performance
8.4.3.3. Type Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. Sonic Healthcare Limited
8.4.4.1. Company Overview
8.4.4.2. Financial Performance
8.4.4.3. Type Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. H.U. Group Holdings, Inc.
8.4.5.1. Company Overview
8.4.5.2. Financial Performance
8.4.5.3. Type Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. Kindstar Globalgene Technology, Inc.
8.4.6.1. Company Overview
8.4.6.2. Financial Performance
8.4.6.3. Type Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. Stanford Health Care
8.4.7.1. Company Overview
8.4.7.2. Financial Performance
8.4.7.3. Type Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. Mayo Foundation for Medical Education and Research
8.4.8.1. Company Overview
8.4.8.2. Financial Performance
8.4.8.3. Type Benchmarking
8.4.8.4. Strategic Initiatives
8.4.9. ARUP Laboratories
8.4.9.1. Company Overview
8.4.9.2. Financial Performance
8.4.9.3. Type Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. Athena Esoterix
8.4.10.1. Company Overview
8.4.10.2. Financial Performance
8.4.10.3. Type Benchmarking
8.4.10.4. Strategic Initiatives
8.4.11. ACM Global Laboratories
8.4.11.1. Company Overview
8.4.11.2. Financial Performance
8.4.11.3. Type Benchmarking
8.4.11.4. Strategic Initiatives
8.4.12. Healius Limited.
8.4.12.1. Company Overview
8.4.12.2. Financial Performance
8.4.12.3. Type Benchmarking
8.4.12.4. Strategic Initiatives